Meet Olof Breuer, MD, Clinical pharmacology lead
As a Clinical Pharmacologist at Karolinska University Hospital, Olof Breuer skillfully combines his medical expertise with a consultant role. He plays a crucial part at the hospital’s successful consulting business, delivering specialized advice in clinical pharmacology to various businesses.
When Olof Breuer was approached by PharmNovo in 2021 and asked whether he could help with clinical pharmacology consultancy services, the decision was easy.
“Most team members have a scientific background and are much driven by science and facts which, combined with an open atmosphere for discussion, fosters creativity. Working in such a team is a delight," says Olof Breuer.
Olof Breuer is appointed Clinical Pharmacology Lead, a strategic move that underscores PharmNovo's commitment to success. His extensive background in the pharmaceutical industry, with roles ranging from medical adviser to principal scientist, project manager, and clinical pharmacology director, equips Olof Breuer with a comprehensive understanding of the intricacies of drug development.
"I bring over 25 years of experience in drug development, of which 17 were spent in different roles within small and big pharma companies, for example, KaroBio and AstraZeneca. In addition, my current job as a senior consultant in the Clinical Trials Unit at the Clinical Pharmacology department within Karolinska University Hospital also brings hands-on clinical perspectives of pharmacokinetics, daily health care, and clinical trials."
An essential facet of Olof Breuer's skill set is his proficiency as a trained pharmacokinetics. By combining modelling and simulation techniques, Olof makes the design of studies and data analysis more efficient. This speeds up the research work and distils relevant data for decision-making, which is crucial when developing drugs.
"The fact that I am a "data analysis nerd" helps a lot in data mining so that potential problems can be identified early on and mitigated."
Olof's passion for addressing unmet medical needs, particularly in pain management, aligns perfectly with PharmNovo's mission to change the lives of people suffering from neuropathic pain.
"Research and development encompass problem-solving and creativity, which I consider important factors for job satisfaction. For me, such factors also add to the meaning of life."
Meet Olof Breuer, MD, Clinical pharmacology lead
As a Clinical Pharmacologist at Karolinska University Hospital, Olof Breuer skillfully combines his medical expertise with a consultant role. He plays a crucial part at the hospital’s successful consulting business, delivering specialized advice in clinical pharmacology to various businesses.
When Olof Breuer was approached by PharmNovo in 2021 and asked whether he could help with clinical pharmacology consultancy services, the decision was easy.
“Most team members have a scientific background and are much driven by science and facts which, combined with an open atmosphere for discussion, fosters creativity. Working in such a team is a delight," says Olof Breuer.
Olof Breuer is appointed Clinical Pharmacology Lead, a strategic move that underscores PharmNovo's commitment to success. His extensive background in the pharmaceutical industry, with roles ranging from medical adviser to principal scientist, project manager, and clinical pharmacology director, equips Olof Breuer with a comprehensive understanding of the intricacies of drug development.
"I bring over 25 years of experience in drug development, of which 17 were spent in different roles within small and big pharma companies, for example, KaroBio and AstraZeneca. In addition, my current job as a senior consultant in the Clinical Trials Unit at the Clinical Pharmacology department within Karolinska University Hospital also brings hands-on clinical perspectives of pharmacokinetics, daily health care, and clinical trials."
An essential facet of Olof Breuer's skill set is his proficiency as a trained pharmacokinetics. By combining modelling and simulation techniques, Olof makes the design of studies and data analysis more efficient. This speeds up the research work and distils relevant data for decision-making, which is crucial when developing drugs.
"The fact that I am a "data analysis nerd" helps a lot in data mining so that potential problems can be identified early on and mitigated."
Olof's passion for addressing unmet medical needs, particularly in pain management, aligns perfectly with PharmNovo's mission to change the lives of people suffering from neuropathic pain.
"Research and development encompass problem-solving and creativity, which I consider important factors for job satisfaction. For me, such factors also add to the meaning of life."
Latest news
View all
Positive FDA feedback for PN6047
PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.
Read more
Pioneering approach to treat neuropathic pain
PharmNovo has recently published an article in MedNous, highlighting the pioneering approach to tackling neuropathic pain without the risks traditionally associated with opioids. The lead candidate, PN6047, targets the delta-opioid receptor – offering pain relief without addiction or sedation. Arrangements for a Phase II trial have now been completed, marking a crucial step toward a safer alternative for millions suffering from chronic pain. With the opioid crisis still a major concern, innovative, non-addictive treatments like PN6047 are more urgent than ever.
Read more
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more